

Vishwanath venketaraman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3634010/publications.pdf>

Version: 2024-02-01

82
papers

2,770
citations

172457

29
h-index

197818

49
g-index

85
all docs

85
docs citations

85
times ranked

3258
citing authors

#	ARTICLE	IF	CITATIONS
1	Liposomes as Carriers for the Delivery of Efavirenz in Combination with Glutathione – An Approach to Combat Opportunistic Infections. <i>Applied Sciences (Switzerland)</i> , 2022, 12, 1468.	2.5	4
2	Liposomal Glutathione Helps to Mitigate Mycobacterium tuberculosis Infection in the Lungs. <i>Antioxidants</i> , 2022, 11, 673.	5.1	7
3	TB and COVID-19: An Exploration of the Characteristics and Resulting Complications of Co-infection. <i>Frontiers in Bioscience - Scholar</i> , 2022, 14, 6.	2.1	18
4	Type 2 Diabetes Contributes to Altered Adaptive Immune Responses and Vascular Inflammation in Patients With SARS-CoV-2 Infection. <i>Frontiers in Immunology</i> , 2022, 13, 833355.	4.8	8
5	Protective Efficacy of BCG Vaccine against Mycobacterium leprae and Non-Tuberculous Mycobacterial Infections. <i>Vaccines</i> , 2022, 10, 390.	4.4	9
6	The Effects of Oral Liposomal Glutathione and In Vitro Everolimus in Altering the Immune Responses against Mycobacterium bovis BCG Strain in Individuals with Type 2 Diabetes. <i>Biomolecular Concepts</i> , 2021, 12, 16-26.	2.2	6
7	A review of the BCG vaccine and other approaches toward tuberculosis eradication. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 2454-2470.	3.3	18
8	Analysis of COVID-19 on Diagnosis, Vaccine, Treatment, and Pathogenesis with Clinical Scenarios. <i>Clinics and Practice</i> , 2021, 11, 309-321.	1.4	6
9	Mechanisms of Nausea and Vomiting: Current Knowledge and Recent Advances in Intracellular Emetic Signaling Systems. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5797.	4.1	64
10	Effects of Oral Liposomal Glutathione in Altering the Immune Responses Against Mycobacterium tuberculosis and the Mycobacterium bovis BCG Strain in Individuals With Type 2 Diabetes. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 657775.	3.9	14
11	Effects of Glutathione Diminishment on the Immune Responses against Mycobacterium tuberculosis Infection. <i>Applied Sciences (Switzerland)</i> , 2021, 11, 8274.	2.5	6
12	Exploring Potential COPD Immunosuppression Pathways Causing Increased Susceptibility for MAC Infections among COPD Patients. <i>Clinics and Practice</i> , 2021, 11, 619-630.	1.4	4
13	Hyperlipidemia and Obesity's Role in Immune Dysregulation Underlying the Severity of COVID-19 Infection. <i>Clinics and Practice</i> , 2021, 11, 694-707.	1.4	3
14	Review of the Effectiveness of Various Adjuvant Therapies in Treating Mycobacterium tuberculosis. <i>Infectious Disease Reports</i> , 2021, 13, 821-834.	3.1	3
15	Everolimus-induced effector mechanism in macrophages and survivability of Erdman, CDC1551 and HN878 strains of Mycobacterium tuberculosis infection. <i>Biomolecular Concepts</i> , 2021, 12, 46-54.	2.2	3
16	Analysis of the Delta Variant B.1.617.2 COVID-19. <i>Clinics and Practice</i> , 2021, 11, 778-784.	1.4	198
17	SARS-CoV-2 and the Immune Response in Pregnancy with Delta Variant Considerations. <i>Infectious Disease Reports</i> , 2021, 13, 993-1008.	3.1	24
18	Root Causes of Fungal Coinfections in COVID-19 Infected Patients. <i>Infectious Disease Reports</i> , 2021, 13, 1018-1035.	3.1	30

#	ARTICLE	IF	CITATIONS
19	The preclinical candidate indole-2-carboxamide improves immune responses to Mycobacterium tuberculosis infection in healthy subjects and individuals with type 2 diabetes. International Microbiology, 2020, 23, 161-170.	2.4	6
20	Pathogenesis of Human Immunodeficiency Virus-Mycobacterium tuberculosis Co-Infection. Journal of Clinical Medicine, 2020, 9, 3575.	2.4	22
21	General Overview of Nontuberculous Mycobacteria Opportunistic Pathogens: Mycobacterium avium and Mycobacterium abscessus. Journal of Clinical Medicine, 2020, 9, 2541.	2.4	119
22	Cyclic Peptide [R4W4] in Improving the Ability of First-Line Antibiotics to Inhibit Mycobacterium tuberculosis Inside in vitro Human Granulomas. Frontiers in Immunology, 2020, 11, 1677.	4.8	5
23	Recent Advances in Mycobacterial Research. Journal of Clinical Medicine, 2020, 9, 2650.	2.4	2
24	A Role of Intracellular Toll-Like Receptors (3, 7, and 9) in Response to Mycobacterium tuberculosis and Co-Infection with HIV. International Journal of Molecular Sciences, 2020, 21, 6148.	4.1	14
25	The Role of Dendritic Cells in TB and HIV Infection. Journal of Clinical Medicine, 2020, 9, 2661.	2.4	11
26	Understanding the Relationship between Glutathione, TGF- β 2, and Vitamin D in Combating Mycobacterium tuberculosis Infections. Journal of Clinical Medicine, 2020, 9, 2757.	2.4	6
27	Analysis of Tuberculosis Meningitis Pathogenesis, Diagnosis, and Treatment. Journal of Clinical Medicine, 2020, 9, 2962.	2.4	13
28	Antimycobacterial Effects of Everolimus in a Human Granuloma Model. Journal of Clinical Medicine, 2020, 9, 2043.	2.4	26
29	Glutathione Supplementation as an Adjunctive Therapy in COVID-19. Antioxidants, 2020, 9, 914.	5.1	48
30	Thyroid Hormone Resistant Syndrome. Medical Journal of Southern California Clinicians, 2020, , 6-10.	0.2	0
31	Potentials of Host-Directed Therapies in Tuberculosis Management. Journal of Clinical Medicine, 2019, 8, 1166.	2.4	20
32	Elucidating the Efficacy of the Bacille Calmette-Guérin Vaccination in Conjunction with First Line Antibiotics and Liposomal Glutathione. Journal of Clinical Medicine, 2019, 8, 1556.	2.4	7
33	Flavonoid Mixture Inhibits Mycobacterium tuberculosis Survival and Infectivity. Molecules, 2019, 24, 851.	3.8	14
34	Investigating the Role of Everolimus in mTOR Inhibition and Autophagy Promotion as a Potential Host-Directed Therapeutic Target in Mycobacterium tuberculosis Infection. Journal of Clinical Medicine, 2019, 8, 232.	2.4	43
35	Type 2 Diabetes Mellitus and Altered Immune System Leading to Susceptibility to Pathogens, Especially Mycobacterium tuberculosis. Journal of Clinical Medicine, 2019, 8, 2219.	2.4	93
36	Cigarette Smoking and Increased Susceptibility to Mycobacterium tuberculosis Infection. , 2018, , 111-125.		1

#	ARTICLE	IF	CITATIONS
37	The Synergistic Effects of the Glutathione Precursor, NAC and First-Line Antibiotics in the Granulomatous Response Against Mycobacterium tuberculosis. <i>Frontiers in Immunology</i> , 2018, 9, 2069.	4.8	38
38	Novel Antimycobacterial Drugs and Host-Directed Therapies for Tuberculosis. , 2018, , 99-109.		0
39	Glutathione as a Marker for Human Disease. <i>Advances in Clinical Chemistry</i> , 2018, 87, 141-159.	3.7	115
40	Selenium Supplementation, Antioxidant Effects, and Immune Restorative Effects in Human Immunodeficiency Virus — All authors contributed equally.. , 2018, , 197-205.		0
41	Opportunistic Infections in HIV Individuals and Enhanced Immunity by Glutathione — , 2018, , 135-147.		1
42	Effects of ReadiSorb L-GSH in Altering Granulomatous Responses against Mycobacterium tuberculosis Infection. <i>Journal of Clinical Medicine</i> , 2018, 7, 40.	2.4	15
43	Characterizing the Effects of Glutathione as an Immunoadjuvant in the Treatment of Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	24
44	Restoring Cytokine Balance in HIV-Positive Individuals with Low CD4 T Cell Counts. <i>AIDS Research and Human Retroviruses</i> , 2017, 33, 905-918.	1.1	37
45	Effector Mechanisms of Neutrophils within the Innate Immune System in Response to Mycobacterium tuberculosis Infection. <i>Journal of Clinical Medicine</i> , 2017, 6, 15.	2.4	37
46	Glutathione, Immunity, and Infection. , 2017, , 375-386.		0
47	Data on pro-inflammatory cytokines IL-1 β , IL-17, and IL-6 in the peripheral blood of HIV-infected individuals. <i>Data in Brief</i> , 2016, 8, 1044-1047.	1.0	6
48	Analysis of glutathione levels in the brain tissue samples from HIV-1-positive individuals and subject with Alzheimer's disease and its implication in the pathophysiology of the disease process. <i>BBA Clinical</i> , 2016, 6, 38-44.	4.1	26
49	Complement 3 Receptor Expression in Individuals with Type 2 Diabetes. <i>Recent Patents on Anti-infective Drug Discovery</i> , 2016, 11, 174-182.	0.8	1
50	Mechanisms of Control of Mycobacterium tuberculosis by NK Cells: Role of Glutathione. <i>Frontiers in Immunology</i> , 2015, 6, 508.	4.8	87
51	Editorial: Causes for Increased Susceptibility to Mycobacterium tuberculosis — A Close View of the Immune System. <i>Frontiers in Immunology</i> , 2015, 6, 545.	4.8	0
52	Investigating the Causes for Decreased Levels of Glutathione in Individuals with Type II Diabetes. <i>PLoS ONE</i> , 2015, 10, e0118436.	2.5	81
53	Mycobacterium tuberculosis. <i>Journal of Immunology Research</i> , 2015, 2015, 1-2.	2.2	5
54	Liposomal Glutathione Supplementation Restores T _H 1 Cytokine Response to Mycobacterium tuberculosis Infection in HIV-Infected Individuals. <i>Journal of Interferon and Cytokine Research</i> , 2015, 35, 875-887.	1.2	57

#	ARTICLE	IF	CITATIONS
55	Investigating the Role of Threonylcarbamoyl Adenosine in HIV-1 Replication in vivo. FASEB Journal, 2015, 29, 711-19.	0.5	0
56	Glutathione synthesis is compromised in erythrocytes from individuals with HIV. Frontiers in Pharmacology, 2014, 5, 73.	3.5	40
57	Glutathione and infection. Biochimica Et Biophysica Acta - General Subjects, 2013, 1830, 3329-3349.	2.4	130
58	Glutathione Supplementation Improves Macrophage Functions in HIV. Journal of Interferon and Cytokine Research, 2013, 33, 270-279.	1.2	47
59	Characterization of Dendritic Cell and Regulatory T Cell Functions against Mycobacterium tuberculosis Infection. BioMed Research International, 2013, 2013, 1-14.	1.9	20
60	An Elucidation of Neutrophil Functions against Mycobacterium tuberculosis Infection. Clinical and Developmental Immunology, 2013, 2013, 1-11.	3.3	18
61	Unveiling the Mechanisms for Decreased Glutathione in Individuals with HIV Infection. Clinical and Developmental Immunology, 2012, 2012, 1-10.	3.3	67
62	Control of Mycobacterium tuberculosis growth by activated natural killer cells. Clinical and Experimental Immunology, 2012, 168, 142-152.	2.6	67
63	Preparation of liposomal vancomycin and intracellular killing of methicillin-resistant Staphylococcus aureus (MRSA). International Journal of Antimicrobial Agents, 2011, 37, 140-144.	2.5	81
64	Glutathione and Adaptive Immune Responses against Mycobacterium tuberculosis Infection in Healthy and HIV Infected Individuals. PLoS ONE, 2011, 6, e28378.	2.5	70
65	Global View of HIV Infection. , 2011, , .		7
66	Atherosclerosis: pathogenesis and increased occurrence in individuals with HIV and Mycobacterium tuberculosis infection. HIV/AIDS - Research and Palliative Care, 2010, 2, 211.	0.8	4
67	Dendritic cells in infectious disease, hypersensitivity, and autoimmunity. International Journal of Interferon, Cytokine and Mediator Research, 2010, , 137.	1.1	3
68	Control of Mycobacterium tuberculosis Infection by Glutathione. Recent Patents on Anti-infective Drug Discovery, 2009, 4, 214-226.	0.8	17
69	Glutathione levels and immune responses in tuberculosis patients. Microbial Pathogenesis, 2008, 44, 255-261.	2.9	76
70	Both leukotoxin and poly-N-acetylglucosamine surface polysaccharide protect Aggregatibacter actinomycetemcomitans cells from macrophage killing. Microbial Pathogenesis, 2008, 45, 173-180.	2.9	37
71	Natural Killer Cells, Glutathione, Cytokines, and Innate Immunity Against Mycobacterium tuberculosis. Journal of Interferon and Cytokine Research, 2008, 28, 153-165.	1.2	56
72	Glutathione and growth inhibition of Mycobacterium tuberculosis in healthy and HIV infected subjects. AIDS Research and Therapy, 2006, 3, 5.	1.7	39

#	ARTICLE	IF	CITATIONS
73	Arginine Homeostasis in J774.1 Macrophages in the Context of Mycobacterium bovis BCG Infection. Journal of Bacteriology, 2006, 188, 4830-4840.	2.2	37
74	Characterization of a Glutathione Metabolic Mutant of Mycobacterium tuberculosis and Its Resistance to Glutathione and Nitrosoglutathione. Journal of Bacteriology, 2006, 188, 1364-1372.	2.2	54
75	Glutathione and Nitrosoglutathione in Macrophage Defense against Mycobacterium tuberculosis. Infection and Immunity, 2005, 73, 1886-1889.	2.2	86
76	Nitric oxide regulation of l-arginine uptake in murine and human macrophages. Tuberculosis, 2003, 83, 311-318.	1.9	14
77	Modulation of J774.1 Macrophage l- Arginine Metabolism by Intracellular Mycobacterium bovis BCG. Infection and Immunity, 2003, 71, 1011-1015.	2.2	14
78	Role of Glutathione in Macrophage Control of Mycobacteria. Infection and Immunity, 2003, 71, 1864-1871.	2.2	74
79	Effects of Mycobacterium bovis BCG Infection on Regulation of l-Arginine Uptake and Synthesis of Reactive Nitrogen Intermediates in J774.1 Murine Macrophages. Infection and Immunity, 2001, 69, 5823-5831.	2.2	22
80	Cytolytic P2X purinoceptors. Cell Death and Differentiation, 1998, 5, 191-199.	11.2	243
81	Role of Cytokines and Chemokines in HIV Infection. , 0, , .		3
82	L-GSH Supplementation in Conjunction With Rifampicin Augments the Treatment Response to Mycobacterium tuberculosis in a Diabetic Mouse Model. Frontiers in Pharmacology, 0, 13, .	3.5	8